Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.23 AUD
Change Today +0.005 / 2.22%
Volume 55.3K
IMC On Other Exchanges
Symbol
Exchange
OTC US
As of 8:55 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

immuron ltd (IMC) Snapshot

Open
A$0.23
Previous Close
A$0.23
Day High
A$0.23
Day Low
A$0.23
52 Week High
08/26/14 - A$0.32
52 Week Low
03/31/15 - A$0.15
Market Cap
17.2M
Average Volume 10 Days
83.7K
EPS TTM
A$-0.05
Shares Outstanding
75.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMURON LTD (IMC)

Related News

No related news articles were found.

immuron ltd (IMC) Related Businessweek News

No Related Businessweek News Found

immuron ltd (IMC) Details

Immuron Limited, a biopharmaceutical company, researches, develops, and sells polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its platform technology enables the development of medicines that target a range of medical needs, such as infectious diseases, immune mediated disorders, and cancers. The company commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. It markets Travelan, a natural product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travellers’ diarrhoea. The company is also developing IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/Type 2 diabetes, which is under Phase II clinical trial; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Southbank, Australia.

16 Employees
Last Reported Date: 08/29/14
Founded in 1994

immuron ltd (IMC) Top Compensated Officers

External Advisor
Total Annual Compensation: A$192.0K
Compensation as of Fiscal Year 2013.

immuron ltd (IMC) Key Developments

Immuron Appoints Dan Ruben Peres as Senior Vice President of Innovation

Immuron Limited announced the appointment of Dr. Dan Ruben Peres as Senior Vice President of Innovation. In this newly created role, Dr. Peres will be responsible for leading and managing Immuron's Phase II clinical trial program currently underway for non-alcoholic steatohepatitis (NASH) and to support a US National Institute of Health (NIH) funded Phase II clinical trial program for alcoholic steatohepatitis (ASH). Dr. Peres has served in various clinical and medical managerial roles in pharmaceutical and medical device companies such as Exalenz Biosciences, CarboFix Orthopedics Ltd, NMB Medical Applications Ltd, ByPass Makafim Ltd, IOPtima Ltd. and NovoNordisk Israel. In addition, Dr. Peres has been responsible for operational, marketing and business-development activities throughout his career in the life sciences industry.

Immuron Limited Appoints Peter Anastasiou as Director

Immuron Limited announced the appointment of Mr. Peter Anastasiou to serve as a Director of the company. Mr. Anastasiou is a serial entrepreneur and investor with extensive experience in business both in Australia and overseas. Mr. Anastasiou was the founding Chairman of the ACSI Group of Companies, Britex Carpet care, Rug Doctor and Crystal Clear.

Immuron Ltd Secures First Orders for its Travelan Product in the US

Immuron Ltd. has secured first orders for its Travelan product in the US from the US travel medicine chain with more than 240 clinics providing travel medicine services nationwide. Travelan is now available for sale in Australia, Canada and the US, and is undergoing regulatory approval in China. It is marketed as a dietary supplement in the US, and can be sold through pharmacists, drug stores and general stores. The volume of initial US orders from travel clinics was higher than anticipated, and orders are expected to build with the potential for significant revenue as the US rollout gains momentum.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMC:AU A$0.23 AUD +0.005

IMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMC.
View Industry Companies
 

Industry Analysis

IMC

Industry Average

Valuation IMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.5x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMURON LTD, please visit www.immuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.